干细胞治疗（stem cells）

干细胞治疗（stem cells） 泰国绝对健康再生医学中心（Absolute Health）创立于2005年，旗下拥有全泰12间综合及专科诊疗中心并拥有亚洲唯一ACESO生物技术实验室、个性化定制药房及制药厂。被评为亚洲领先的再生医学集团。

Materials Today Bio: Dual-Targeted Engineered MSC-EVs Deliver Nedd4 to Reverse Renal Fibrosis in DKDA breakthrough from ...
15/07/2026

Materials Today Bio: Dual-Targeted Engineered MSC-EVs Deliver Nedd4 to Reverse Renal Fibrosis in DKD

A breakthrough from Materials Today Bio: SPION-EVs-Nedd4 – a dual magnetic and biological targeted cell-free platform. Superparamagnetic nanoparticles guide MSC-derived EVs precisely to injured kidneys, delivering Nedd4 to degrade NUAK1, block YAP signaling, and halt collagen deposition – the irreversible core of diabetic kidney disease. Cell-free, safer than live cell transplantation. A novel translational strategy.


Materials Today Bio发表：双靶向工程化MSC-EVs递送Nedd4逆转糖尿病肾病肾纤维化

发表于《Materials Today Bio》的研究带来突破：SPION-EVs-Nedd4双靶向无细胞平台——超顺磁纳米粒子引导MSC来源细胞外囊泡精准靶向受损肾脏，递送Nedd4蛋白降解NUAK1、阻断YAP信号通路、终止胶原沉积，逆转糖尿病肾病不可逆的肾纤维化核心病变。无细胞疗法，避免活细胞移植风险，为DKD治疗提供全新转化策略。
#糖尿病肾病 #肾纤维化 #间充质干细胞外囊泡 #靶向治疗 #无细胞疗法 #肾脏修复 #纳米医学

New Combined Stem Cell Therapy for Diabetic Nephropathy Now Launched in Top Tertiary Hospitals – Renal Artery Infusion D...
15/07/2026

New Combined Stem Cell Therapy for Diabetic Nephropathy Now Launched in Top Tertiary Hospitals – Renal Artery Infusion Doubles Lesion Targeting

A new clinical regimen upgrades diabetic nephropathy care: minimally invasive renal artery infusion delivers double the effective MSC concentration directly to injured kidneys. Combined with hypoglycemic and immune drugs, this multi-target approach suppresses inflammation, decomposes fibrosis, repairs microvessels, and improves insulin resistance – relieving albuminuria, creatinine, edema, and nocturia. Best for stage I-IV early/mid-stage patients. Only ethical trials in formal top hospitals.


糖尿病肾病联合干细胞新疗法落地三甲医院——肾动脉微创输注使病灶区细胞浓度翻倍

一项糖尿病肾病治疗新方案实现升级：经肾动脉微创输注，使干细胞在受损肾脏的靶向浓度提升一倍。联合降糖药与免疫药，多靶点协同抗炎、分解纤维化、修复微血管、改善胰岛素抵抗，有效缓解蛋白尿、肌酐、水肿和夜尿等症状。对I-IV期早中期患者效果最优。务必选择正规三甲医院的合规临床试验。
#糖尿病肾病 #联合治疗 #肾动脉输注 #间充质干细胞 #肾脏修复 #抗纤维化 #微血管修复 #三甲医院 #临床试验 #再生医学

NEPHSTROM 18-Month JASN Data Confirms: Single MSC Infusion Significantly Slows Diabetic Kidney DeclinePublished in JASN,...
14/07/2026

NEPHSTROM 18-Month JASN Data Confirms: Single MSC Infusion Significantly Slows Diabetic Kidney Decline
Published in JASN, the European multi-center NEPHSTROM trial with 18-month full follow-up proves: one infusion of CD362-selected high-activity allogeneic MSCs significantly reduced annual eGFR decline vs placebo. Four repair mechanisms – immune regulation, fibrosis blockade, microvascular repair, and paracrine-driven regeneration. Excellent safety, no severe adverse events. Ideal for early DKD patients with progressive decline and microvascular complications.


NEPHSTROM 18个月JASN数据证实：单次MSC输注显著延缓糖尿病肾病进展
发表于《JASN》的欧洲多中心NEPHSTROM试验完成18个月完整随访，证实单次输注CD362筛选的高活性异体MSCs可使年eGFR下降显著缓于安慰剂组。四大修复机制：免疫调节、阻断纤维化、修复微血管、旁分泌促再生。安全性优异，无严重治疗相关不良事件。适用于早期DKD、肾功能进行性下降伴微血管并发症患者。
#糖尿病肾病 #间充质干细胞 #肾脏保护 #微血管修复 #临床试验 #再生肾脏病学 #干细胞治疗

Jilin University Review: MSCs Reverse Renal Damage in Diabetic Nephropathy – From Delay to RepairPublished in the Chines...
14/07/2026

Jilin University Review: MSCs Reverse Renal Damage in Diabetic Nephropathy – From Delay to Repair
Published in the Chinese Journal of Cell and Stem Cell, this evidence-based review confirms MSCs do more than slow progression – they actively reverse renal injury. Four core mechanisms: protect kidney cells via oxidative stress relief and mitochondrial repair; suppress inflammation and rebalance macrophages; eliminate fibrosis and scar tissue; plus innovative epigenetic and gut-kidney axis regulation. 8-year follow-up proves safety. New hope for millions.


吉林大学团队综述：间充质干细胞逆转糖尿病肾病肾损伤——从延缓走向修复
发表于《中华细胞与干细胞杂志》的循证综述确认，MSCs不止延缓肾病进展，更能主动逆转肾损伤。四大核心机制：保护肾细胞（缓解氧化应激、修复线粒体）、抗炎（抑制炎症因子、调节巨噬细胞平衡）、抗纤维化（消除肾瘢痕、修复血管），以及表观遗传调控和肠-肾轴调控等创新路径。8年长期随访证实安全性良好，为数百万糖尿病肾病患者提供新希望。
#糖尿病肾病 #间充质干细胞 #肾脏修复 #抗纤维化 #肾脏健康 #干细胞研究 #中华细胞与干细胞杂志 #吉林大学 #再生医学 #糖尿病并发症

Single MSC Infusion: 70% Diabetic Nephropathy Patients See Kidney Improvement at 6 Months – GFR Rises 1.94 vs Declines 4...
13/07/2026

Single MSC Infusion: 70% Diabetic Nephropathy Patients See Kidney Improvement at 6 Months – GFR Rises 1.94 vs Declines 4.0 in Placebo
A 91-patient randomized double-blind trial (78 completed 6-month follow-up) delivers compelling results: one IV infusion of 30 million MSCs improved renal function in 70% of patients vs just 27.4% in placebo. GFR rose by 1.94 in the MSC group but fell by 4.0 in controls. HbA1c also significantly dropped – dual kidney and glycemic benefits. Anti-inflammatory, anti-fibrotic, glomerular repair.


单次输注MSCs：70%糖尿病肾病患者6个月肾功能改善——GFR上升1.94，安慰组下降4.0
一项91名患者入组、78人完成6个月随访的随机双盲试验显示：单次静脉输注3000万个MSCs，70%患者肾功能获得改善，而安慰剂组仅为27.4%。MSC组GFR上升1.94，对照组下降4.0。糖化血红蛋白同步显著下降，实现肾脏与血糖双重获益。抗炎、抗纤维化、修复肾小球。
#糖尿病肾病 #间充质干细胞 #肾功能 #随机试验 #双盲 #糖尿病管理 #肾脏修复 #血糖控制 #干细胞研究

Rilparencel Autologous Cell Therapy Cuts eGFR Decline by 78% in Advanced Diabetic Nephropathy – Phase II DataA Phase II ...
13/07/2026

Rilparencel Autologous Cell Therapy Cuts eGFR Decline by 78% in Advanced Diabetic Nephropathy – Phase II Data
A Phase II trial of 53 advanced DKD patients (eGFR 20–50) shows: two bilateral renal cortex injections of autologous Rilparencel reduced annual eGFR decline by 78% – far outperforming standard kidney-protective drugs. Sustained kidney function maintenance over 18 months, good safety profile, no severe product-related events. Global Phase III now underway. From slowing progression to preserving nephrons.


自体细胞疗法Rilparencel使晚期糖尿病肾病年eGFR下降减缓78%——II期临床数据发布
一项纳入53名晚期糖尿病肾病患者（eGFR 20–50）的II期随机试验显示：双侧肾皮质两次注射自体Rilparencel细胞，年eGFR下降幅度减缓78%，效果远优于传统保肾药物。18个月随访期内肾功能持续维持，安全性良好，无严重产品相关事件。全球III期试验正在进行中，从延缓进展走向肾单位主动保存。
#糖尿病肾病 #自体细胞治疗 #肾功能 #肾脏修复 #肾单位保护 #再生肾脏病学 #临床试验

Single 80M MSC Infusion Slashes Kidney Function Decline by 73% in Diabetic Nephropathy – 18-Month JASN DataThe NEPHSTROM...
10/07/2026

Single 80M MSC Infusion Slashes Kidney Function Decline by 73% in Diabetic Nephropathy – 18-Month JASN Data
The NEPHSTROM trial published in JASN delivers breakthrough data: one IV infusion of 80 million CD362-selected bone marrow MSCs cut annual eGFR decline from -4.35 to -1.18 mL/min/1.73m² – a 73% slowdown in kidney function loss. MSCs stabilized inflammatory monocytes and preserved regulatory T cells. 18-month follow-up, good safety profile. A single shot, lasting protection.


单次输注8000万MSCs使糖尿病肾病肾功能年下降减缓73%——JASN 18个月数据发布
发表于《JASN》的NEPHSTROM试验带来突破性数据：单次静脉输注8000万CD362筛选的骨髓间充质干细胞，将年eGFR下降从-4.35减缓至-1.18 mL/min/1.73m²——肾功能丧失速度减缓73%。MSCs稳定炎症单核细胞、维持调节性T细胞。18个月随访，安全性良好。一次输注，持续保护。
#糖尿病肾病 #间充质干细胞 #肾功能 #骨髓干细胞 #糖尿病并发症 #肾脏保护 #临床试验

104 Patients, 6 Trials: MSCs Raise eGFR by 4.62 mL/min – A Real Kidney Repair SignalPublished in BMC Nephrology (2026), ...
10/07/2026

104 Patients, 6 Trials: MSCs Raise eGFR by 4.62 mL/min – A Real Kidney Repair Signal
Published in BMC Nephrology (2026), this meta-analysis of 104 nephropathy patients across 6 trials delivers a clear message: mesenchymal stem cells do more than slow damage – they actively improve renal function. Average eGFR increased by 4.62 mL/min/1.73m². MSCs regulate immune overdrive, block fibrosis, and repair damaged renal vessels. Safe, with no severe adverse events vs placebo. From dialysis waiting list to real tissue repair.


104例患者、6项试验证实：间充质干细胞让肾病患者eGFR提升4.62个单位
2026年发表于《BMC Nephrology》的荟萃分析纳入104名肾病患者的6项临床试验，传递明确信号：间充质干细胞不只是延缓损伤，而是主动改善肾功能——平均eGFR升高4.62 mL/min/1.73m²。MSCs通过调节免疫、阻断纤维化、修复肾血管实现肾脏修复。安全性与安慰剂无显著差异，无严重并发症。从等待透析走向主动修复。
#肾脏疾病 #间充质干细胞 #肾病 #肾脏修复 #糖尿病肾病 #狼疮性肾炎 #再生医学 #肾脏健康

58 Trials, 262 T2DM Patients: MSCs Cut Fasting Glucose 45%, HbA1c 32%, Boost C-Peptide 38% in 12 MonthsA 5-year meta-ana...
09/07/2026

58 Trials, 262 T2DM Patients: MSCs Cut Fasting Glucose 45%, HbA1c 32%, Boost C-Peptide 38% in 12 Months
A 5-year meta-analysis of 58 clinical trials across 262 type 2 diabetes patients shows powerful results: 45% fasting glucose drop, 32% HbA1c reduction, and 38% C-peptide improvement at 12 months. China leads with 39 stem cell diabetes trials nationwide – Peking University Shenzhen Hospital reports 75% of patients reduced hypoglycemic drugs by 10%-50%, with one patient fully drug-free. Beyond glucose, MSCs also show positive effects on diabetic foot, retinopathy, and nephropathy.


58项临床试验、262名2型糖尿病患者：间充质干细胞12个月空腹血糖降45%、糖化血红蛋白降32%、C肽提升38%
一项覆盖58项临床试验、262名2型糖尿病患者的5年荟萃分析证实：12个月时空腹血糖平均下降45%，糖化血红蛋白降低32%，C肽改善38%。中国已开展39项干细胞糖尿病临床试验，其中9项使用脐带间充质干细胞——北京大学深圳医院数据显示，75%患者降糖药减少10%-50%，1例完全停药。MSCs还对糖尿病足、视网膜病变、肾病等并发症显示积极效果。
#间充质干细胞 #2型糖尿病 #荟萃分析 #血糖控制 #胰岛修复 #糖尿病并发症 #北京大学 #干细胞研究 #糖尿病管理

Meta-Analysis of 20 RCTs: Stem Cell Therapy Cuts Type 2 Diabetes Insulin Use by 35.7 Units at 24 MonthsA comprehensive m...
09/07/2026

Meta-Analysis of 20 RCTs: Stem Cell Therapy Cuts Type 2 Diabetes Insulin Use by 35.7 Units at 24 Months
A comprehensive meta-analysis of 20 global RCTs (427 stem cell patients vs 351 controls, follow-up 3–96 months) confirms: insulin drops 14.42U at 6 months, 17.79U at 12 months, and 35.73U at 24 months – with the best effect seen at 2 years. Fasting C-peptide rises 0.25 nmol/L, HbA1c falls 1.60%, proving real β-cell repair. 301 Hospital double-blind trial and Boao Lecheng pilot launch further validate this breakthrough.


20项RCT荟萃分析证实：干细胞治疗让2型糖尿病患者24个月胰岛素日用量减少35.7单位
一项纳入全球20项随机对照试验、427名干细胞治疗患者、随访3至96个月的荟萃分析显示：6个月胰岛素日用量减少14.42单位，12个月减少17.79单位，24个月减少35.73单位，效果随时间递增。空腹C肽升高0.25nmol/L，糖化血红蛋白下降1.60%，证明胰岛β细胞获得真实修复。301医院双盲试验与博鳌乐城先行区落地进一步验证这一突破。
#2型糖尿病 #干细胞治疗 #荟萃分析 #减少胰岛素 #胰岛修复 #脐带间充质干细胞 #301医院 #糖尿病研究 #临床试验 #再生医学

Address

20 / 2-7 Ruamrudee Village Project Soi Ruamrudee Community, Lumphini, Pathum Wan, Bangkok 10330
Alawwa

Telephone

+66917846058

Website

Alerts

Be the first to know and let us send you an email when 干细胞治疗（stem cells） posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to 干细胞治疗（stem cells）:

Shortcuts

Share

Category